COMMUNIQUÉS West-GlobeNewswire

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
26/01/2026
Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “ [...]
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
26/01/2026
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical- [...]
Primmune Therapeutics Announces Additional Close of Series B Financing
26/01/2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total [...]
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of [...]
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB [...]
New Clinical Data Demonstrate that VIVUS’ QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity
26/01/2026
— Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight at 12 months compared with DELI alone CAMPBELL, [...]
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
26/01/2026
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Invention of DNA "Page Numbers" Opens Up Vast Possibilities for the Bioeconomy
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology PASADENA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- The power of artificial intelligence (AI) and [...]
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
26/01/2026
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in [...]
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE [...]
Coloplast A/S - Q1 2025/26 Earnings Release - Invitation for conference call on 6 Feb 2026 at 11.00am CET
26/01/2026
Friday, 6 February 2026 at 11:00-12:00am CET In connection with the publication of Coloplast’s interim financial results for Q1 2025/26, to be released same day around 07.30am CET, Coloplast will host a conference call [...]
QHSLab (OTCQB:USAQ) Reports Preliminary Unaudited 2025 Financial Results With Strong Revenue Growth, Expanding Margins, and Significant Debt Reduction
26/01/2026
Revenue increased 25% year over year, gross margins expanded to approximately 67%, and convertible debt was substantially eliminated Improved profitability and early Q-Cog reimbursement activity position the Company for [...]
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured patients Launch [...]
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
26/01/2026
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI [...]
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
26/01/2026
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD Company to host satellite symposium on diagnostic and [...]
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026
MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- BlueOcean Global Corp., a medical device company focused on limb preservation and complex reconstruction, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance [...]
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026
10XB-101 Being Developed for Focal Fat Reduction and Body Contouring LA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic [...]
Cannara publie ses résultats pour le premier trimestre de l’exercice 2026, enregistre de nouveaux résultats financiers records, accroît ses parts de marché et poursuit sa stratégie d’expansion disciplinée
26/01/2026
Nouveaux résultats financiers records : revenus totaux de 30,1 millions de dollars, marge brute avant ajustements de la juste valeur de 13,5 millions de dollars, soit 45 %, et BAIIA ajusté de 8,8 millions de dollars 1 [...]
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next- [...]

Pages